BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 392179)

  • 1. [Vitamin D metabolism in kidney insufficiency: disorders of an endocrine regulatory zone].
    Ritz E; Kreusser W; Boland R; Bommer J
    Klin Wochenschr; 1979 Oct; 57(19):1053-9. PubMed ID: 392179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D and type II sodium-dependent phosphate cotransporters.
    Kido S; Kaneko I; Tatsumi S; Segawa H; Miyamoto K
    Contrib Nephrol; 2013; 180():86-97. PubMed ID: 23652552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D metabolites and bone mineralization in man.
    Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
    J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
    Schömig M; Ritz E
    Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in our understanding of the vitamin D endocrine system.
    De Luca HF
    J Lab Clin Med; 1976 Jan; 87(1):7-26. PubMed ID: 173767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in pediatric metabolic bone disease: the consequences of altered phosphate homeostasis in renal insufficiency and hypophosphatemic vitamin D-resistant rickets.
    Pettifor JM
    Bone Miner; 1990 Jun; 9(3):199-214. PubMed ID: 2163713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D: the discovery of its metabolites and their therapeutic applications.
    Beale MG; Chan JC; Oldham SB; Deluca HF
    Pediatrics; 1976 May; 57(5):729-41. PubMed ID: 181725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D and the parathyroid.
    Beckerman P; Silver J
    Am J Med Sci; 1999 Jun; 317(6):363-9. PubMed ID: 10372835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of vitamin D: current status.
    DeLuca HF
    Am J Clin Nutr; 1976 Nov; 29(11):1258-70. PubMed ID: 187053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.
    Cozzolino M; Gallieni M; Brancaccio D; Arcidiacono T; Bianchi G; Vezzoli G
    J Nephrol; 2006; 19(5):566-77. PubMed ID: 17136683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in vitamin D metabolism as they pertain to chronic renal disease.
    Coburn JW; Hartenbower DL; Brickman AS
    Am J Clin Nutr; 1976 Nov; 29(11):1283-99. PubMed ID: 187055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin secretion in uremia: effect of parathyroid hormone and vitamin D metabolites.
    Mak RH
    Kidney Int Suppl; 1989 Nov; 27():S227-30. PubMed ID: 2699996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part IV of IV parts: The state of the bones in uremic hyperaparathyroidism--the mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis.
    Parfitt AM
    Metabolism; 1976 Oct; 25(10):1157-88. PubMed ID: 787723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D: recent advances.
    DeLuca HF; Schnoes HK
    Annu Rev Biochem; 1983; 52():411-39. PubMed ID: 6311080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal expression and regulation of vitamin D receptor in experimental uremia.
    Szabó A; Ritz E; Schmidt-Gayk H; Reichel H
    Nephron; 1996; 73(4):619-28. PubMed ID: 8856261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium and phosphorus metabolism in chronic uremia.
    Fiaschi E; Mioni G; Maschio G; D'Angelo A; Ossi E
    Nephron; 1975; 14(2):163-80. PubMed ID: 1093055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calreticulin inhibits vitamin D's action on the PTH gene in vitro and may prevent vitamin D's effect in vivo in hypocalcemic rats.
    Sela-Brown A; Russell J; Koszewski NJ; Michalak M; Naveh-Many T; Silver J
    Mol Endocrinol; 1998 Aug; 12(8):1193-200. PubMed ID: 9717845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.